T1D Exchange has launched a population health surveillance study of individuals with type diabetes (T1D) who are suspected or confirmed to have contracted COVID-19. The results of the study will be utilized to better understand the etiology and potential outcomes of COVID-19 patients and inform future clinical quality improvement activities to better respond to the global pandemic.
TrialSite News follows up with a Q&A breakdown of this update.
Why is a type 1 diabetes organization putting together a disease registry for to include those that may have COVID-19?
Because it appears that those with pre-existing conditions, such as diabetes, may be more vulnerable to become severely ill if they contract COVID-19. For example, the American Diabetes Association reports that individuals with uncontrolled diabetes are more likely to have worse outcomes and in particular, for individuals with 1TD, an infection could lead to severe adverse outcomes such as diabetic ketoacidosis (DKA) and other serious complications, or possibly even death.
Who is T1D Exchange?
T1D Exchange is a leading provider of real-world evidence, dedicated to improving care for people affected by T1D. T1D Exchange actively supports quality improvement and innovation through its Quality Improvement Collaborative, online patient registry, and data-centric research services. It plays an active role in creating real-world impact with this integrated data by providing clinicians, researchers, industry partners, and advocates with the resources and services they need for better decision support and population health management
What is the benefit of an electronic registry?
T1D’s CEO suggests that the “power of collecting and translating real-world experiences into actionable solutions to improve care” is the underlying driver behind “this important study.” He continued, “We believe that this is the first study that investigates the prevalence, presentation and outcomes of COVID-19 specifically on those living with Type 1 diabetes and the findings will be critical to inform the future of treatment and care.”
Who is Participating in the Study?
The study will commence with 35 diabetic clinics including the 14 member clinics of T1D Exchange’s Quality Improvement Collaborative (QIC), all of whom have already signed up to share ongoing COVID-19 data.
Do Participating clinics need to be a Member of T1D to be in the Study?
No. Non-members can participate.
Who are the study’s lead authors?
Lead authors of the study are Dr. Osagie Ebekozien, Vice President, Population Health and Quality Improvement at T1D Exchange; Dr. Guy Todd Alonso, Barbara Davis Center for Diabetes, Children’s Hospital Colorado; and Dr. Mary Pat Gallagher, Pediatric Diabetes Center, Hassenfeld Children’s Hospital at NYU Langone Health.
What is the Quality Improvement Collaborative?
The Quality Improvement Collaborative (QIC) brings together 14 clinics situated across the US and treating more than 28,000 individuals with type 1 diabetes. The QIC has achieved unprecedented success because it relies on an embedded and systemic approach: individual providers are empowered to identify areas of unmet need within their clinic. They make small changes in care that scale up through the QIC to create best practices, which are then shared among and implemented by members at other clinics.